Abcam, ab120451, Dipyridamole, Non-selective phosphodiesterase (PDE) inhibitor

Size: 1g / 5g / 10g
MW 504.6 Da, Purity >99%. Non-selective phosphodiesterase (PDE) inhibitor. Exerts antiplatelet, anti-inflammatory, antioxidative and antifibrotic effects. Inhibits hydrolysis of cyclic AMP (cAMP) and cGMP (IC 50 = 5 and 3 μM, respectively) in vitro .
Key facts
CAS number:58-32-2,
Purity:>99%,
Form:SolidSee storage information,
Molecular weight:504.6 Da,
Molecular formula:C24H40N8O4,
PubChem:3108,
Nature:Synthetic,
Solubility:Soluble in DMSO to 100 mMSoluble in ethanol to 10 mM,
Biochemical name:Dipyridamole,
Biological description:Non-selective phosphodiesterase (PDE) inhibitor. Exerts antiplatelet, anti-inflammatory, antioxidative and antifibrotic effects. Inhibits hydrolysis of cyclic AMP (cAMP) and cGMP (IC50 = 5 and 3 μM, respectively) in vitro.,
Canonical smiles:C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,
InChi:InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2,
InChiKey:IZEKFCXSFNUWAM-UHFFFAOYSA-N,
IUPAC Name:2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol

Properties and Storage Information:
Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions-Ambient, Appropriate long-term storage conditions-Ambient, Storage information-The product can be stored for up to 12 months

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Hsp90 also known as Heat Shock Protein 90 serves as a molecular chaperone assisting in protein folding stabilization and degradation. It has a molecular weight of approximately 90 kDa. Hsp90 is expressed ubiquitously across various tissues in the human body. Cytochrome P450 proteins including CYP3A4 CYP2C9 CYP2C8 and CYP2C19 are involved in drug metabolism functioning as enzymes primarily located in the liver. The phosphodiesterase (PDE) family including PDE6 alpha beta gamma delta and others breaks down cyclic nucleotides like cAMP and cGMP modulating signaling pathways. ENT1 or Equilibrative Nucleoside Transporter 1 facilitates the transport of nucleosides across membranes playing a critical role in maintaining cellular functions.
Biological function summary
These proteins are integral to diverse physiological processes with Hsp90 stabilizing client proteins often involved in cell growth and survival. Cytochrome P450 enzymes as key components of the mixed-function oxidase system metabolize xenobiotics and endogenous compounds. PDEs such as PDE4 and PDE6 regulate intracellular levels of second messengers cAMP and cGMP impacting signal transduction. ENT1 facilitates nucleoside uptake affecting purine and pyrimidine metabolism. Some of these proteins participate in large complexes like cytochrome P450 enzymes in the electron transport chain essential for their catalytic activity.
Pathways
These proteins are involved in important cellular and metabolic pathways. Hsp90 is a part of the heat shock response and interacts with steroid hormone receptors. Cytochrome P450 enzymes partake in drug metabolism pathways influencing pharmacokinetics of various therapeutics. PDE6 is part of the visual transduction pathway impacting phototransduction in retinal cells. The involvement of PDE4 in inflammatory pathways connects it to the regulation of immune responses. Proteins such as Hsp90 and cytochrome P450 interact with various cellular proteins to mediate these processes.
These proteins are linked to significant pathological conditions. Hsp90 is often associated with cancer as many of its client proteins are oncogenic. Cytochrome P450 mutations or polymorphisms relate to drug metabolism variability impacting conditions like liver disease and affecting drug efficacy or toxicity. PDE6 abnormalities are linked to retinal diseases like retinitis pigmentosa. PDE4's role in inflammation makes it a target for therapeutic intervention in disorders such as asthma and chronic obstructive pulmonary disease (COPD). These connections illustrate the critical nature of understanding these proteins in developing targeted therapies.